NEW YORK, Nov. 17 (GenomeWeb News) - Genmab and ACE BioSciences said today that they have agreed to develop an antibody-based fungicide against a protein target on Aspergillus fumigatus.
The arrangement is part of a broader drug development partnership between the companies under which ACE discovers novel protein targets in four disease areas and Genmab contributes its human antibody technology. The companies share costs and commercialization rights equally under the alliance, they said.
"ACE BioSciences's target discovery skills and Genmab's antibody development capabilities are an ideal combination for discovery and development of antibody based treatments for infectious diseases," Genmab CEO Lisa Drakeman said in a statement. "Fungal infections are becoming an increasingly urgent health threat and, despite not being adequately treated, currently represent a multi-billion dollar market."